[Clinical value of contrast-enhanced ultrasonography in the diagnosis of prostate cancer in patients with different PSA concentrations].
To investigate the clinical value of contrast-enhanced ultrasonography (CEUS) in the diagnosis of prostate cancer in patients with different concentrations of prostate-specific antigen (PSA). Based on the PSA concentration, 186 patients were divided into three groups (PSA 4－10 μg/L, 11－20 μg/L, and >20 μg/L) and underwent transrectal CEUS and biopsy. We compared the pathological results with the CEUS features in different groups of patients and performed a statistical analysis on the characteristics of the CEUS manifestations of prostate cancer and benign prostatic lesions. Of the 186 patients, 118 (63.4%) were diagnosed by biopsy with prostate cancer and the other 68 (36.6%) with benign prostatic lesions. The positive rate of CEUS in the diagnosis of prostate cancer was above 95% in all the three groups, significantly higher than that of conventional ultrasound in the PSA 4－10 and >10－20 μg/L groups (P <0.01). Contrast-enhanced ultrasonography can achieve a high detection rate in the diagnosis of prostate cancer, especially for the patients with a low PSA concentration, and therefore can be used as one of the most valuable diagnostic techniques for this purpose.